A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Status:
RECRUITING
Trial end date:
2028-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension